• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Omnicell Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    5/23/25 4:34:00 PM ET
    $OMCL
    Computer Manufacturing
    Technology
    Get the next $OMCL alert in real time by email
    false 0000926326 0000926326 2025-05-21 2025-05-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D. C.  20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
    1934

     

    Date of Report (Date of earliest event reported): May 21, 2025

     

    OMNICELL, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   000-33043   94-3166458
    (State or other jurisdiction of
    incorporation)
     

    (Commission File Number)

     

    (IRS Employer Identification Number)

     

    4220 North Freeway

    Fort Worth, TX 76137

    (Address of principal executive offices, including zip code)

     

    (877) 415-9990

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class  Trading Symbol  Name of each exchange on which registered
    Common Stock, $0.001 par value  OMCL  NASDAQ Global Select Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

     

     

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

     

    Amendment to the Omnicell, Inc. 2009 Equity Incentive Plan

     

    As described below under Item 5.07 of this Current Report on Form 8-K, at the 2025 Annual Meeting of Stockholders of Omnicell, Inc. (the “Company”) held on May 21, 2025 (the “Annual Meeting”), the Company’s stockholders approved an amendment to the Company’s 2009 Equity Incentive Plan, as amended (as amended, the “Amended 2009 Plan”), which, among other items, added an additional 1,750,000 shares to the number of shares of common stock authorized for issuance under the Amended 2009 Plan.

     

    The Amended 2009 Plan is described in detail in Proposal No. 3 in the Company's Definitive Proxy Statement on Schedule 14A filed with the United States Securities and Exchange Commission on April 3, 2025 (the “Proxy Statement”), and the full text of the Amended 2009 Plan is attached to the Proxy Statement as Appendix A. The description of the Amended 2009 Plan set forth above is a summary only and is qualified in its entirety by reference to the full text of the Amended 2009 Plan, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

     

    Item 5.07. Submission of Matters to a Vote of Security Holders

     

    On May 21, 2025, the Company held its Annual Meeting. Four items of business, which were described in detail in the Proxy Statement, were acted upon by the stockholders at the Annual Meeting. The final voting results regarding each proposal are set forth below.

     

    Proposal No. 1: Election of Three Class III Directors to Hold Office Until the 2028 Annual Meeting of Stockholders

     

    Edward P. Bousa, Mary Garrett, and Bruce E. Scott were elected to serve as members of the Company’s Board of Directors (the “Board”) until the 2028 Annual Meeting of Stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal.

     

    Votes were cast as follows for the election of directors:

     

       For  Withheld  Broker Non-Votes
    Edward P. Bousa  35,421,552  2,264,612  4,279,972
    Mary Garrett  34,722,222  2,963,942  4,279,972
    Bruce E. Scott  34,114,987  3,571,177  4,279,972

     

    Proposal No. 2: Advisory Vote to Approve Named Executive Officer Compensation

     

    The stockholders voted, on an advisory basis, to approve named executive officer compensation by the following vote:

     

    For  Against  Abstain  Broker Non-Votes
    35,780,985  1,724,508  180,671  4,279,972

     

    Proposal No. 3: Approval of an Amendment to the Omnicell, Inc. 2009 Equity Incentive Plan, as Amended

     

    The stockholders voted to approve the Amended 2009 Plan to, among other items, add an additional 1,750,000 shares to the number of shares of common stock authorized for issuance under the Amended 2009 Plan, by the following vote:

     

    For  Against  Abstain  Broker Non-Votes
    35,600,671  1,915,066  170,427  4,279,972

     

     

     

     

    Proposal No. 4: Ratification of the Selection of Independent Registered Public Accounting Firm

     

    The stockholders ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025 by the following vote:

     

    For  Against  Abstain
    41,527,276  166,260  272,600

     

    Item 9.01. Financial Statements and Exhibits

     

    (d) Exhibits.

     

    Exhibit
    Number
      Description of Document
    10.1   Omnicell, Inc. 2009 Equity Incentive Plan, as amended (incorporated by reference to Appendix A to Omnicell, Inc.’s definitive proxy statement on Schedule 14A for the Omnicell, Inc. 2025 Annual Meeting of Stockholders held May 21, 2025 (File No. 000-33043))*
         
    104   Cover Page Interactive Data File (embedded within the inline XBRL document)

     

    * Indicates a management contract, compensation plan, or arrangement.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

     

      OMNICELL, INC.
       
    Date: May 23, 2025 /s/ Corey J. Manley
      Corey J. Manley
      Executive Vice President and Chief Legal and Administrative Officer

     

     

     

    Get the next $OMCL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OMCL

    DatePrice TargetRatingAnalyst
    5/14/2025$35.00Equal Weight → Overweight
    Wells Fargo
    10/31/2024$44.00 → $57.00Buy → Neutral
    BofA Securities
    8/2/2024$26.00 → $39.00Underweight → Equal Weight
    Barclays
    1/3/2024$33.00Underweight
    Barclays
    11/3/2023$39.00 → $28.00Underweight → Equal Weight
    Wells Fargo
    11/3/2023Buy → Neutral
    BTIG Research
    11/3/2023$70.00 → $39.00Neutral → Overweight
    Piper Sandler
    10/11/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $OMCL
    SEC Filings

    See more
    • SEC Form S-8 filed by Omnicell Inc.

      S-8 - OMNICELL, INC. (0000926326) (Filer)

      6/18/25 4:04:58 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - OMNICELL, INC. (0000926326) (Filer)

      6/5/25 5:13:20 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - OMNICELL, INC. (0000926326) (Filer)

      5/23/25 4:34:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Omnicell Expects Improved Profitability, Updates Second Quarter and Full Year 2025 Profit Outlook and Announces a New Stock Repurchase Program

      Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced updates to its second quarter and full year 2025 outlook for Non-GAAP EBITDA and Non-GAAP earnings per share, and the authorization of a new $75 million stock repurchase program. "The Administration's recent announcement of a reduction in tariff rates on imports from China has compelled us to update our second quarter and full-year 2025 outlook to reflect the expected diminished impact on our supply chain and anticipated improved profitability," stated Randall Lipps, chairman, president, chief executive officer,

      5/22/25 8:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Announces New Products for Perioperative and Clinic Settings

      RFID-Enabled Dispensing and Intelligent Inventory Management Software Aim to Unlock Greater Inventory Accuracy and Streamline Medication Management in Operating Rooms and Outpatient Clinics Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced new products designed to streamline workflows and enhance inventory visibility and management in perioperative and clinic settings. These products, which leverage RFID tracking and intelligent software workflows, expand Omnicell's connected platform that is intended to automate medication management processes and deliver intelligent insights to drive clinical

      5/14/25 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Opens New Innovation Lab in Austin, Texas

      Company Establishes New Hub Dedicated to Addressing Challenges Across the Medication Journey Omnicell, Inc. (NASDAQ:OMCL), ("Omnicell" or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced the opening of its Innovation Lab, located at 1005 East St. Elmo Road in Austin, Texas. The facility will serve as a hub focused on addressing challenges along the medication and supply journey and developing new technologies that are designed to solve evolving challenges faced by the healthcare industry. As hospitals and health systems are grappling with rising costs and staffing shortages, we believe that innovative automated technologies will be imp

      5/14/25 8:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHAIRMAN, PRESIDENT AND CEO Lipps Randall A covered exercise/tax liability with 1,146 shares, decreasing direct ownership by 0.28% to 403,523 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      6/17/25 5:27:57 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • EVP&CHIEF LEGAL/ADMIN OFFICER Manley Corey J covered exercise/tax liability with 332 shares, decreasing direct ownership by 0.28% to 117,126 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      6/17/25 5:27:11 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Director Parrish Mark W was granted 6,828 shares, increasing direct ownership by 12% to 65,255 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      6/3/25 4:12:37 PM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHAIRMAN, PRESIDENT AND CEO Lipps Randall A bought $349,874 worth of shares (10,561 units at $33.13) and was granted 79,494 shares, increasing direct ownership by 28% to 413,104 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      3/18/25 4:13:27 PM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Omnicell upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Omnicell from Equal Weight to Overweight and set a new price target of $35.00

      5/14/25 8:50:33 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell downgraded by BofA Securities with a new price target

      BofA Securities downgraded Omnicell from Buy to Neutral and set a new price target of $57.00 from $44.00 previously

      10/31/24 7:49:39 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell upgraded by Barclays with a new price target

      Barclays upgraded Omnicell from Underweight to Equal Weight and set a new price target of $39.00 from $26.00 previously

      8/2/24 7:36:45 AM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

      SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

      12/11/23 9:36:42 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

      SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

      9/11/23 1:33:44 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

      SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

      2/9/23 11:27:45 AM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Financials

    Live finance-specific insights

    See more
    • Omnicell Announces First Quarter 2025 Results

      Omnicell delivers solid first quarter financial results Results exceed previously issued first quarter 2025 guidance for total revenues and non-GAAP EPS Updates full year 2025 non-GAAP EBITDA and non-GAAP EPS guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its first quarter ended March 31, 2025. "We delivered strong financial results for the first quarter of 2025, exceeding our previously provided guidance ranges for both revenue and earnings, which we believe reflects customers embracing the industry-defined vision of the Autonomous P

      5/6/25 6:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell to Release First Quarter 2025 Financial Results on May 6, 2025

      Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the first quarter 2025, before market open on Tuesday, May 6, 2025. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 7437144. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/. About O

      4/14/25 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Announces Fiscal Year and Fourth Quarter 2024 Results

      Omnicell delivers strong fourth quarter financial results Results exceed previously issued full year guidance for bookings, total revenues, and non-GAAP EBITDA Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its fiscal year and fourth quarter ended December 31, 2024. "We delivered solid financial results for the fourth quarter of 2024, including returning to year-over-year revenue growth. We are pleased with the improved execution of the business throughout 2024, including strong free cash flows achieved in the year," stated Randall Lipps, ch

      2/6/25 6:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology